Investors seeking to outperform the market often focus on hand-picking stocks. Selecting the right ones has proven to be a key factor in boosting wealth.
In the latest session, Moderna Inc (NASDAQ: MRNA) closed at $24.43 down -12.25% from its previous closing price of $27.84. In other words, the price has decreased by -$12.25 from its previous closing price. On the day, 23.14 million shares were traded.
Ratios:
For a deeper understanding of Moderna Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 4.14 and its Current Ratio is at 4.22. In the meantime, Its Debt-to-Equity ratio is 0.07 whereas as Long-Term Debt/Eq ratio is at 0.07.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Citigroup on March 13, 2025, initiated with a Neutral rating and assigned the stock a target price of $40.
On February 18, 2025, Barclays Downgraded its rating to Equal Weight which previously was Overweight and also lowered its target price recommendation from $111 to $45.
Goldman Downgraded its Buy to Neutral on January 29, 2025, whereas the target price for the stock was revised from $99 to $51.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Mar 03 ’25 when Bancel Stephane bought 160,314 shares for $31.22 per share. The transaction valued at 5,004,318 led to the insider holds 9,210,686 shares of the business.
SAGAN PAUL bought 31,620 shares of MRNA for $1,004,251 on Mar 03 ’25. The Director now owns 312,027 shares after completing the transaction at $31.76 per share. On Dec 09 ’24, another insider, Klinger Shannon Thyme, who serves as the Chief Legal Officer of the company, sold 529 shares for $44.68 each. As a result, the insider received 23,637 and left with 20,446 shares of the company.
Valuation Measures:
For the stock, the TTM Price-to-Sale (P/S) ratio is 2.97 while its Price-to-Book (P/B) ratio in mrq is 0.94.
Stock Price History:
Over the past 52 weeks, MRNA has reached a high of $170.47, while it has fallen to a 52-week low of $23.15. The 50-Day Moving Average of the stock is -17.77%, while the 200-Day Moving Average is calculated to be -51.95%.
Shares Statistics:
A total of 387.00M shares are outstanding, with a floating share count of 342.48M. Insiders hold about 11.45% of the company’s shares, while institutions hold 67.42% stake in the company.
